Thomas Dominique, Zorn Kevin C, Meskawi Malek, Goueli Ramy, Hueber Pierre-Alain, Deonarine Lesa, Misrai Vincent, Te Alexis, Chughtai Bilal
Department of Urology, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA.
Section of Urology, Department of Surgery, University of Montreal Hospital Center, Montreal, QC, Canada.
Asian J Urol. 2019 Oct;6(4):353-358. doi: 10.1016/j.ajur.2019.01.006. Epub 2019 Jan 25.
Our objective was to characterize the safety and efficacy of the 180 W XPS-GreenLight laser in men with lower urinary tract symptoms secondary to a small volume benign prostatic hyperplasia (BPH).
A retrospective analysis was performed for all patients who underwent 180 W XPS-laser photoselective vaporization of the prostate (PVP) vaporization of the prostate between 2012 and 2016 at two-tertiary medical centers. Data collection included baseline comorbidities, disease-specific quality of life scores, maximum urinary flow rate (Q), postvoid residual (PVR), complications, prostate volume and prostate-specific antigen (PSA). The secondary endpoints were the incidence of intraoperative and postoperative adverse events. Complications were stratified using the Clavien-Dindo grading system up to 90 days after surgery.
Mean age of men was 67.8 years old, with a mean body mass index of 29.7 kg/m. Mean prostate volume as measured by transrectal ultrasound was 29 mL. Anticoagulation use was 47% and urinary retention with catheter at time of surgery was 17%. Mean hospital stay and catheter time were 0.5 days. Median follow-up time was 6 months with the longest duration of follow-up being 22.5 months (interquartile range, 3-22.5 months). The International Prostate Symptom Score improved from 22.8 ± 7.0 at baseline to 10.7 ± 7.4 ( < 0.01) and 6.3 ± 4.4 ( < 0.01) at 1 and 6 months, respectively. The Q improved from 7.70 ± 4.46 mL/s at baseline to 17.25 ± 9.30 mL/s ( < 0.01) and 19.14 ± 7.19 mL/s ( < 0.001) at 1 and 6 months, respectively, while the PVR improved from 216.0 ± 271.0 mL preoperatively to 32.8 ± 45.3 mL ( < 0.01) and 26.2 ± 46.0 mL ( < 0.01) at 1 and 6 months, respectively. The PSA dropped from 1.97 ± 1.76 ng/mL preoperatively to 0.71 ± 0.61 ng/mL ( < 0.01) and 0.74 ± 0.63 ng/mL at 1 and 6 months, respectively. No patient had a bladder neck contracture postoperatively and no capsular perforations were noted intraoperatively.
The 180 W GreenLight XPS system is safe and effective for men with small volume BPH. PVP produced improvements in symptomatic and clinical parameters without any safety concern. It represents a safe surgical option in this under studied population.
我们的目的是评估180W XPS-绿激光治疗继发于小体积良性前列腺增生(BPH)的男性下尿路症状的安全性和有效性。
对2012年至2016年期间在两家三级医疗中心接受180W XPS-激光选择性前列腺汽化术(PVP)的所有患者进行回顾性分析。数据收集包括基线合并症、疾病特异性生活质量评分、最大尿流率(Q)、残余尿量(PVR)、并发症、前列腺体积和前列腺特异性抗原(PSA)。次要终点是术中和术后不良事件的发生率。使用Clavien-Dindo分级系统对术后90天内的并发症进行分层。
男性的平均年龄为67.8岁,平均体重指数为29.7kg/m。经直肠超声测量的平均前列腺体积为29mL。抗凝药物使用率为47%,手术时留置导尿管的尿潴留率为17%。平均住院时间和导尿管留置时间为0.5天。中位随访时间为6个月,最长随访时间为22.5个月(四分位间距,3-22.5个月)。国际前列腺症状评分从基线时的22.8±7.0分别改善至1个月时的10.7±7.4(P<0.01)和6个月时的6.3±4.4(P<0.01)。Q从基线时的7.70±4.46mL/s分别改善至1个月时的17.25±9.30mL/s(P<0.01)和6个月时的19.14±7.19mL/s(P<0.001),而PVR从术前的216.0±271.0mL分别改善至1个月时的32.8±45.3mL(P<0.01)和6个月时的26.2±46.0mL(P<0.01)。PSA从术前的1.97±1.76ng/mL分别降至1个月时的0.71±0.61ng/mL(P<0.01)和6个月时的0.74±0.63ng/mL。术后无患者发生膀胱颈挛缩,术中未发现包膜穿孔。
180W绿激光XPS系统对小体积BPH男性患者安全有效。PVP改善了症状和临床参数,且无任何安全问题。它是这一研究较少人群的一种安全手术选择。